BBV-154 Vaccine: A clinical trial of Corona's BBV-154 intranasal vaccine has got a big achievement

Bharat Biotech International Limited announced that BBV154 has been proven to be safe, tolerable, and immunogenic in controlled clinical trials.

BBV-154 Vaccine: A clinical trial of Corona's BBV-154 intranasal vaccine has got a big achievement

The country's first intranasal Covid vaccine is going to be available soon. There on the occasion of Independence Day, the country has got a big achievement in the war against Corona. In fact, Bharat Biotech has completed the third clinical trial of Corona's BBV-154 intranasal vaccine. This vaccine can be given as a booster dose. Bharat Biotech International Limited announced that BBV154 has been proven to be safe, tolerable, and immunogenic in controlled clinical trials.

Dr. Krishna Ella, President, and MD of Bharat Biotech said that Bharat Biotech International Limited will apply for the license soon. Bharat Biotech said that the first and second clinical trials of the BBV-154 intranasal vaccine were conducted. During the trial, the vaccine was given in the first and second doses. After successful testing, it was also tested as a booster dose. However, booster doses were given to the same people. Who had got both the vaccines of Covid?

The data of both the human clinical trials of Phase III have been sent to the National Regulatory Authorities for approval. Several levels were tested during the first dose trial. During this, every aspect of safety and immunogenicity was carefully checked. Along with this, it was compared with COVAXINÒ. Bharat Biotech conducted trials at 14 locations across India.

The company had said that the vaccine dose given to healthy volunteers in the first phase of clinical trials worked well. No serious adverse events have been reported. The vaccine was found to be safe, immunogenic, and well-functioning in pre-clinical toxicity studies.

The booster dose of Intra Nasal Vaccine was tested at 9 locations. Bharat Biotech will be given through the nose (Nasal Corona Vaccine). The central government launched Mission Covid Suraksha last year so that work on the corona vaccine can be done at the earliest. The focus of this mission is to make available a safe, effective, affordable, and accessible COVID vaccine to the people.